Dr. Jane Apperley CML Chronic Myeloid Leukemia
|
Professor of Medicine
Chair, Department of Haematology Division of Investigative Science Imperial College School of Medicine Hammersmith Hospital London, United Kingdom ''Her particular interests are the biology and management of chronic myeloid leukemia, which has led naturally to an extensive experience in stem cell transplantation and more recently, to the use of signal transduction inhibitors in this disease.'' Extract of Background by ReachMD |
 |
Pregnancy in Chronic Myeloid
Leukemia VIDEO
December 2012, iCMLf
Second generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia who have failed imatinib therapy
August 18, 2011, Haematologica
CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
November 23, 2010, OncologyStat - CMLSupport
Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London – 2005
March 13, 2006, Bone Marrow Transplantation
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission
July 1, 2000, Journal Blood
December 2012, iCMLf
Second generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia who have failed imatinib therapy
August 18, 2011, Haematologica
CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
November 23, 2010, OncologyStat - CMLSupport
Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London – 2005
March 13, 2006, Bone Marrow Transplantation
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission
July 1, 2000, Journal Blood
